“It’s simple, convenient and precise.” says Dr. Steffen Lissner, Product Manager at LAP. Users in the field of radiation therapy worldwide benefit from laser systems from LAP within treatment workflows and individual irradiation planning.

The DORADOnova 5 laser system provides highest comfort and optimal time efficiency during patient positioning and marking. Five movable lasers allow a fully flexible shifting of the projected reference points on the patient. Hence the clinical staff can pay their full attention to the patient, transferring the information of the patient’s position to the treatment room. In the next step room lasers from LAP guide the user to the correct position of the patient – reproducible fraction by fraction.

Lasers for patient positioning increase safety and precision during the whole treatment chain. From the first step of planning to the last irradiation of the patient, precise reproducible positioning saves valuable time. Marking the patient’s reference point on the CT makes it needless to mark on the LINAC which leads to more treatment time.
Five movable lasers for sagittal, coronal and transverse body plane make it easy to mark the patient without moving the CT couch. The clinical staff operate the lasers comfortably and seamless via smart laser control CARINAnav. Users can choose between three different laser colors, green, red and blue, to meet all room and staff requirements.

“We get feedback from users all over the world that the lasers are an important and reliable tool in their daily work.” Dr. Steffen Lissner states. Users rely on the functionality and high quality of radiation therapy solutions from LAP. Not least because all products from LAP meet certification standards for medical devices.

Background: Insights into the biology of chemotherapy resistance may suggest novel strategies to treat Acute Myeloid Leukemia (AML). We examined the role of hyperbaric oxygen (HBO) in AML sensitivity to chemotherapy, oxygen consumption, reactive oxygen species (ROS) generation, glycolytic pathway activation, and gene expression.

Methods: Human AML cell lines HL-60 and MV-411 were treated with cytarabine followed by HBO (100% oxygen at 2.5 atmosphere absolutes for 2 hours in an in vitro HBO chamber) or normobaric culture conditions. At 24 hours, cells were analyzed for proliferation, apoptosis and oxygen consumption. Studies of HBO- treated cells without chemotherapy included CellROX Oxidative Stress assay and real-time PCR with primer sets specific for human hexokinase2 and phosphofructokinase to examine HBO effects on glycolysis. Gene expression profiling by the Human Transcriptome Array 2.0 (Affymetrix) examined differences in gene expression following HBO in HL-60 cells and AML patient samples.

Results: Leukemia cells treated with HBO and cytarabine demonstrated reduced proliferation and increased late apoptosis confirming increased sensitivity to cytarabine. Treatment with HBO plus cytarabine resulted in increased oxygen consumption measured by the seahorse assay at 24 hours post-HBO in MV-411 cells compared to cytarabine alone. Significant increases in ROS levels were observed at 24 hours post-HBO for both cell lines when compared to non-treated cells. Glycolysis pathway components human hexokinase 2 and phosphofructokinase were upregulated in HL60 and MV411 cells treated with HBO compared to controls. Gene expression profiling showed that approximately 200 genes in coding regions were upregulated in HBO-treated HL-60 cells; specific piRNA clusters were downregulated in both AML cell line HL60 and an AML bone marrow sample when treated with HBO.

Conclusions: HBO treatment significantly increases the sensitivity to cytarabine in AML cell lines in vitro, an effect associated with increased late apoptosis and changes in cellular respiration. Increased ROS, upregulation of glycolysis-related enzymes and changes in gene expression profiling provide insight into potential mechanisms of HBO in AML.